Breast implant‑associated anaplastic large‑cell lymphoma and the role of brentuximab vedotin (SGN‑35) therapy: A case report and review of the literature

  • Authors:
    • Kristin Richardson
    • Taha Alrifai
    • Kelly Grant‑Szymanski
    • George J. Kouris
    • Parameswaran Venugopal
    • Brett Mahon
    • Reem Karmali
  • View Affiliations

  • Published online on: Friday, February 17, 2017
  • DOI: 10.3892/mco.2017.1170
0

Abstract

Breast implant-associated (BIA) anaplastic large-cell lymphoma (ALCL) is a rare disease, comprising a small percentage of all non‑Hodgkin lymphomas (NHLs), reportedly 2‑3%. There is currently no established standard approach to the treatment of BIA ALCL. The first case on the development of ALCL in the presence of a breast implant was reported in 1997 and the association was first identified by the Food and Drug Administration in 2011. We herein describe a case of BIA ALCL in a patient with a previous history of breast cancer and breast reconstruction who presented with hardening of her breast implant. The patient underwent capsulectomy and the findings of the pathological examination were consistent with ALCL. The patient completed three cycles of combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP regimen) followed by radiation consolidation therapy, and has maintained a complete remission ever since. The aim of the present study was to review the treatment options for BIA ALCL and suggest an investigation of the CD30‑directed antibody‑drug conjugate, brentuximab vedotin, as a potential treatment option for BIA ALCL.

Related Articles

Journal Cover

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Richardson, K., Alrifai, T., Grant‑Szymanski, K., Kouris, G.J., Venugopal, P., Mahon, B., & Karmali, R. (1899). Breast implant‑associated anaplastic large‑cell lymphoma and the role of brentuximab vedotin (SGN‑35) therapy: A case report and review of the literature. Molecular and Clinical Oncology, 0, 0-0. http://dx.doi.org/10.3892/mco.2017.1170
MLA
Richardson, K., Alrifai, T., Grant‑Szymanski, K., Kouris, G. J., Venugopal, P., Mahon, B., Karmali, R."Breast implant‑associated anaplastic large‑cell lymphoma and the role of brentuximab vedotin (SGN‑35) therapy: A case report and review of the literature". Molecular and Clinical Oncology 0.0 (1899): 0-0.
Chicago
Richardson, K., Alrifai, T., Grant‑Szymanski, K., Kouris, G. J., Venugopal, P., Mahon, B., Karmali, R."Breast implant‑associated anaplastic large‑cell lymphoma and the role of brentuximab vedotin (SGN‑35) therapy: A case report and review of the literature". Molecular and Clinical Oncology 0, no. 0 (1899): 0-0. http://dx.doi.org/10.3892/mco.2017.1170